Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases.
OBJECTIVE
The Radiation Therapy Oncology Group (RTOG) previously developed three prognostic classes for brain metastases using recursive partitioning analysis (RPA) of a large database. These classes were based on Karnofsky performance status (KPS), primary tumor status, presence of extracranial system metastases, and age. An analysis of RTOG 91-04, a randomized study comparing two dose-fractionation schemes with a comparison to the established RTOG database, was considered important to validate the RPA classes.


METHODS
A total of 445 patients were randomized on RTOG 91-04, a Phase III study of accelerated hyperfractionation versus accelerated fractionation. No difference was observed between the two treatment arms with respect to survival. Four hundred thirty-two patients were included in this analysis. The majority of the patients were under age 65, had KPS 70-80, primary tumor controlled, and brain-only metastases. The initial RPA had three classes, but only patients in RPA Classes I and II were eligible for RTOG 91-04.


RESULTS
For RPA Class I, the median survival time was 6. 2 months and 7.1 months for 91-04 and the database, respectively. The 1-year survival was 29% for 91-04 versus 32% for the database. There was no significant difference in the two survival distributions (p = 0.72). For RPA Class II, the median survival time was 3.8 months for 91-04 versus 4.2 months for the database. The 1-year survival was 12% and 16% for 91-04 and the database, respectively (p = 0.22).


CONCLUSIONS
This analysis indicates that the RPA classes are valid and reliable for historical comparisons. Both the RTOG and other clinical trial organizers should currently utilize this RPA classification as a stratification factor for clinical trials.
Gaspar
L E
LE
University of Colorado Health Science Center, Denver, CO, USA. laurie.gaspar@uchsc.edu
Scott
C
C
Murray
K
K
Curran
W
W
D000367:Age Factors; D000368:Aged; D001932:Brain Neoplasms / Q000145:classification* / Q000532:radiotherapy / Q000556:secondary; D019583:Dose Fractionation, Radiation; D006801:Humans; D017567:Karnofsky Performance Status; D008875:Middle Aged; D015203:Reproducibility of Results; D016019:Survival Analysis